InvestorsHub Logo
Followers 3
Posts 908
Boards Moderated 0
Alias Born 02/07/2016

Re: None

Thursday, 02/10/2022 9:32:53 AM

Thursday, February 10, 2022 9:32:53 AM

Post# of 8893
Brand new trial posted today:

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

https://clinicaltrials.gov/ct2/show/NCT05232825?term=Rhuph20&draw=4&rank=116
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News